Demographic, clinical and echocardiography determinants of B-type natriuretic peptide plasma concentration. A population-based study

Revista Portuguesa de Cardiologia

Volumn 26, Issue 2, 2007, Pages 105-113

  Azevedo, Ana ^a   Bettencourt, Paulo ^b   Barros, Henrique ^b  

^a Faculdadde de Medicina do Porto   (Portugal)

^b NONE

Author keywords

Diagnosis; Heart failure; Population based study

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CREATININE CLEARANCE; DEMOGRAPHY; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; SYSTOLIC DYSFUNCTION; BLOOD; CROSS-SECTIONAL STUDY; ECHOGRAPHY; HEART DISEASE; MIDDLE AGED;

CROSS-SECTIONAL STUDIES; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN;

EID: 34247189167     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998; 351: 9-13.
2. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001; 141: 367-74.
3. Kato J, Kitamura K, Uemura T, et al. Plasma levels of adrenomedullin and atrial and brain natriuretic peptides in the general population: their relations to age and pulse pressure. Hypertens Res. 2002; 25: 887-92.
4. Bettencourt P, Ferreira A, Dias P, Castro A, Martins L, Cerqueira-Gomes M. Evaluation of brain natriuretic peptide in the diagnosis of heart failure. Cardiology. 2000; 93: 19-25.
5. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in the assessment of patients with possible new heart failure in primary care. Lancet. 1997; 350: 1349-53.
6. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre JE. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ. 2002; 324: 1492-52.
7. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Eng J Med. 2002; 347: 161-7.
8. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA. 2002; 288: 1252-9.
9. Rose GA, Blackburn H. Cardiovascular survey methods. World Health Organization Monograph. 1986; 56: 1-188.
10. American Diabetes Association: clinical practice recommendations 1997. Diabetes Care. 1997; 20 Suppl 1: S1-70.
11. Cockroft DW, Gault NH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
12. Devereux R, Reichek N. Echocardiography determination of left ventricular mass in men: anatomic validation of the method. Circulation 1977; 55: 613-618.
13. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure). 2001. American College of Cardiology website. Available at:http://www.acc.org/clinical/guidelines/failure/hf_index.htm
14. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003; 326: 219.
15. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002; 40: 976-82.
16. Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptide for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail. 2003; 5: 599-606.
17. Maffei S, Del Ry S, Prontera C, Clerico A. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. Clin Sci. 2001; 101: 447-53.
18. Yamamoto K, Burnett J Jr, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996; 28: 988-94.
19. Bettencourt P, Ferreira A, Sousa T, et al. Brain natriuretic peptide as a marker of cardiac involvement in hypertension. Int J Cardiol. 1999; 69: 169-77.
20. Lang CC, Prasad N, McAlpine HM, et al. Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction. Am Heart J. 1994; 127: 1635-6.
21. Wang TJ, Larson MG, Levy D, et al. Heritability and Genetic Linkage of Plasma Natriuretic Peptide Levels. Circulation. 2003; 108: 13-6.
22. Matsuda M, Matsuda Y. Mechanism of left atrial enlargement related to ventricular diastolic impairment in hypertension. Clin Cardiol. 1996; 19: 954-9.
23. Simek CL, Feldman MD, Haber HL, Wu CC, Jayaweera AR, Kaul S. Relationship between left ventricular wall thickness and left atrial size: comparison with other measures of diastolic function. J Am Soc Echocardiogr. 1995; 8: 37-47.
24. Gottdiener JS, Reda DJ, Williams DW, Materson BJ. Left atrial size in hypertensive men: influence of obesity, race and age. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. J Am Coll Cardiol. 1997; 29: 651-8.
25. Kurtoglu N, Akdemir R, Yuce M, Basaran Y, Dindar I. Left ventricular inflow normal or pseudonormal. A new echocardiographic method: diastolic change of left atrial diameter. Echocardiography. 2000; 17: 653-8.
26. Ueda R, Yokouchi M, Suzuki T, Otomo E, Katagini T. Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. Am J Med. 2003; 114: 266-70.
27. Wallen T, Landahl S, Hender T, Nakao K, Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart. 1997; 77: 264-7.
28. Troughton RW, Frampton CM, Yandle TG, Espinar EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000; 355: 1126-30.
29. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 2001; 7: 21-9.
30. Murdoch DR, McDonagh TA, Byrne J, et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 1999; 138: 1126-32.
31. Kohno M, Minami M, Kano H, et al. Effect of angiotensin-converting enzyme inhibitor on left ventricular parameters and circulating brain natriuretic peptide in elderly hypertensives with left ventricular hypertrophy. Metabolism. 2000; 49: 1356-60.
32. Kawai K, Hata K, Takaoka H, Kawai H, Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. Am Heart J. 2001; 141: 925-32.
33. Fujimura M, Yasumura Y, Ishida Y, et al. Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. J Card Fail. 2000; 6: 3-10.
34. Bettencourt P, Frioes F, Azevedo A, Dias P, Pimenta J, Rocha-Gonçalves F, Ferreira A. Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol 2004; 93: 45-48